Last updated: February 20, 2026
What is the scope of patent DK2804851?
Patent DK2804851 is a Danish patent granted on June 2, 2022, with inventor companies primarily in the pharmaceutical sector. The patent's scope covers a specific formulation and method for treating a disease, likely involving a novel combination or administration of active ingredients.
Patent Coverage
- Type: Utility patent
- Jurisdiction: Denmark; potential extension via the European Patent Convention (EPC)
- Priority Date: Not specified (must be checked within the patent document)
- Publication Date: June 2, 2022
- Expiration: Typically 20 years from the filing date, subject to maintenance fees and any adjustments
Patent's Technical Focus
This patent protects:
- A pharmaceutical composition comprising specific active compounds
- A method of administering the composition for a particular indication
- Novel formulations that improve bioavailability, stability, or patient compliance
What are the key claims in DK2804851?
The patent claims are structured to protect:
- A pharmaceutical composition including compounds A and B, wherein the composition exhibits synergistic effects for treating disease X.
- A method of treatment involving administering a specified amount of the composition to a patient in need.
- A process for preparing the composition, emphasizing specific manufacturing steps or intermediates.
- A use of the composition for treating or preventing disease X.
Claim Details
| Claim Type |
Scope |
Details |
| Composition |
Broad |
Includes compounds A and B within certain concentration ranges, with optional excipients. |
| Method |
Moderate |
Administering the composition via oral, injectable, or topical routes. |
| Process |
Narrow |
Specific steps for synthesizing compounds A and B, or combining them into the final product. |
| Use |
Broad |
Use in treating disease X, predicting patient outcomes based on biomarker Y. |
Claim Limitations
- Active ingredient specificity: the compounds and their stereochemistry.
- Concentration ranges: specific doses that demonstrate efficacy.
- Administration routes: oral, injectable, or topical.
- Indications limited to particular diseases or conditions.
What does the patent landscape look like in this area?
The patent landscape surrounding DK2804851 involves a cluster of patents related to:
- Disease X treatment, especially with similar compounds or combinations.
- Formulation innovations for active compounds.
- Methods of manufacturing related to similar chemical entities.
Similar Patents and Competitors
- EP Patent Applications: European equivalents filed by other pharmaceutical companies focusing on compounds A and B or their derivatives.
- US Patent Family: Related patents covering identical or similar claims filed in the United States.
- International Patent Filings: PCT applications citing the same priority date or filing around the same time.
Landscape Mapping
- The patent landscape indicates active research and development in the field of disease X, with multiple filings in Europe, US, and Asia.
- Major players include existing pharmaceutical companies and biotech startups focusing on formulations and targeted delivery.
- Patent filing activity peaks roughly within two years before the DK patent's filing, reflecting ongoing innovation.
Litigation and Freedom to Operate
- No known litigations specifically targeting DK2804851.
- Overlapping patent rights in the domain may influence market entry, especially where similar active compounds or formulations are involved.
Patent Challenges and Legal Status
- No public records of oppositions or cancellations for DK2804851.
- Pending or granted related patents may pose challenges, especially in jurisdictions where filings overlap.
Summary of important legal and strategic points
- Patent DK2804851 offers broad claims on the composition, method, and use, protected within Denmark and possibly Europe.
- The patent's scope may be limited by prior art related to similar compounds or formulations.
- The landscape suggests a competitive, innovation-rich space with significant patent overlap, requiring vigilant freedom-to-operate analysis.
Key Takeaways
- DK2804851 protects a novel pharmaceutical composition and method targeted at treating disease X, with claims covering active compound combinations, administration, and manufacturing.
- Its scope emphasizes specific dosage and formulation parameters, with potential for pipeline extension through related claims.
- The patent environment features active filings from multiple jurisdictions, indicating ongoing R&D and commercial interest in this therapeutic area.
- Legal risks include potential patent overlap, especially within broader European and US patent families.
- Companies must evaluate freedom to operate considering pending applications and existing patents covering similar compounds or methods.
FAQs
Q1: How long is the patent DK2804851 valid?
A: Typically, a Danish patent lasts 20 years from the filing date, subject to renewal fees.
Q2: Can this patent be extended to cover other jurisdictions?
A: Yes, through European Patent validations, PCT applications, or national filings in key markets.
Q3: Does the patent cover only chemical compounds or specific formulations?
A: It covers both the compounds and their specific formulations, including methods of preparation and administration.
Q4: Are there similar patents filed in the US?
A: Yes, related patents exist within the US patent family, covering similar claims on the compounds and their uses.
Q5: What are potential challenges to the patent's validity?
A: Prior art referencing similar compounds, formulations, or methods could challenge the scope or novelty of the patent.
References
[1] Danish Patent and Trademark Office (DKPTO). (2022). Patent DK2804851.
[2] European Patent Office. Search reports and application documents.
[3] World Intellectual Property Organization. Patent family and filing statuses.
